Mersana Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update
November 09, 2021 06:00 ET
|
Mersana Therapeutics, Inc.
Reported updated data from the UpRi ovarian cancer expansion cohort further bolstering confidence in UPLIFT registration strategyIntroduced UP-NEXT, a Phase 3 study of UpRi monotherapy maintenance in...
Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2021 Financial Results and Business Updates
November 02, 2021 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 27, 2021 16:05 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership
October 25, 2021 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Target and Presents New Preclinical Data for XMT-2056, First Immunosynthen STING-Agonist ADC, at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
October 07, 2021 16:05 ET
|
Mersana Therapeutics, Inc.
Preclinical data demonstrate that XMT-2056 activates the STING pathway in a target-dependent manner in both tumor cells and tumor-resident immune cells and is significantly more efficacious in...
Mersana Therapeutics to Announce Target and Present New Preclinical Data for XMT-2056 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
September 30, 2021 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Present at Upcoming Investor Conferences
September 07, 2021 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Provide Update on the Progress of its UpRi Clinical Development Strategy and Report Interim Data from the Ovarian Cancer Expansion Cohort of the UpRi Phase I Study
September 01, 2021 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 18, 2021 16:05 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Appointment of Tushar Misra, Ph.D., as Chief Manufacturing Officer
August 16, 2021 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...